Daratumumab with chemo for older adults with high-risk AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 study tests whether adding daratumumab to standard intensive chemotherapy (idarubicin and cytarabine) works safely in people age 60 or older with a higher-risk form of acute myeloid leukemia (AML). It may help improve outcomes, but the main goal is to find the best dosing and safety in this age group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 60 years old
- Your AML is considered higher-risk (poor prognosis) by the study’s criteria
- You can receive intensive chemotherapy (your treating team says it’s appropriate) and your performance status is ECOG 2 or less
- Your organ function labs are within limits: liver enzymes < 3x normal, bilirubin < 1.5x normal, kidney filtering > 60 mL/min
- Heart function is strong enough (LVEF 50% or higher)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the drug daratumumab to usual chemotherapy helps children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL). The goal is to see if the combination improves outcomes without increasing side effects.
This trial tests a new combination of a targeted drug (daratumumab) plus chemotherapy, followed by a stem cell transplant, for people with a rare and aggressive blood cancer called primary plasma cell leukemia. The goal is to see if adding daratumumab improves the chances of getting rid of the cancer and staying in remission.
This trial tests if adding the drug daratumumab can clear remaining cancer cells in people with T-cell acute lymphoblastic leukemia (T-ALL) who still have a small amount of leukemia after initial chemotherapy. It aims to reduce the risk of the cancer coming back.
This trial tests a drug called daratumumab for people with aplastic anemia that hasn't improved with standard treatments. The goal is to see if it can help your bone marrow make more blood cells and improve your blood counts.
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
This Phase 2 trial tests daratumumab (a targeted antibody medicine) in people with T-cell ALL whose leukemia is not fully gone at very low levels. The goal is to eliminate “minimal residual disease” (MRD) that can predict relapse, so treatment may be more effective after intensive chemotherapy.
Hear when a new Adult Patients With Adverse Risk Acute Myeloblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.